What is Wedbush's Estimate for VERA Q1 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Vera Therapeutics in a note issued to investors on Tuesday, May 6th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.95) for the quarter. Wedbush currently has a "Neutral" rating and a $26.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.02) EPS and Q4 2026 earnings at ($0.83) EPS.

Several other research analysts have also recently commented on VERA. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Guggenheim lifted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. HC Wainwright assumed coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a "buy" rating and a $75.00 target price on the stock. Cantor Fitzgerald reduced their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $63.80.

Vera Therapeutics Trading Down 1.2 %

NASDAQ:VERA traded down $0.26 on Thursday, hitting $21.77. 1,262,456 shares of the stock were exchanged, compared to its average volume of 778,875. The stock has a fifty day moving average of $24.22 and a 200-day moving average of $34.68. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The stock has a market cap of $1.39 billion, a PE ratio of -8.34 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the firm earned ($0.56) EPS.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VERA. Barclays PLC increased its position in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after acquiring an additional 41,394 shares during the period. SG Americas Securities LLC increased its stake in Vera Therapeutics by 116.7% during the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock valued at $857,000 after acquiring an additional 10,916 shares during the period. KBC Group NV raised its holdings in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Vera Therapeutics by 27.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company's stock worth $568,000 after acquiring an additional 2,882 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Vera Therapeutics by 82.0% during the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after purchasing an additional 366,763 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.